EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Influence of Fusobacterium nucleatum on Tumor Necrosis Factor Alpha Therapy in Ulcerative Colitis

Bilge Şenyüz iD, Nalan Gülşen Ünal iD, Başak Doğanavşargil Yakut iD, Ataç Uzel iD, Cumhur Gündüz iD, Sunde Yılmaz Süslüer iD

Mediators of Inflammation · 2025-01 · 2025 (1)

DOI: 10.1155/mi/5035877 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Mediators of Inflammation, online erschienen am 31.10.2025. Verfasst von Bilge Şenyüz und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biology, Ege University Faculty of Medicine, Izmir, Türkiye. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Fusobacterium nucleatum, Tumor Necrosis Factor-alpha. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inflammatory bowel disease (IBD), including ulcerative colitis (UC), involves chronic gastrointestinal inflammation, with tumor necrosis factor alpha (TNF‐α) playing a key role. Anti‐TNF therapy is widely used, but not all UC patients respond, suggesting additional contributing factors. Gut microbiota alterations, particularly dysbiosis, may influence treatment outcomes. This study examines the relationship between Fusobacterium nucleatum ( F. nucleatum ) density and TNF‐α expression in UC patients receiving anti‐TNF therapy. Biopsy samples from responders ( n = 10), nonresponders ( n = 10), and healthy controls ( n = 10) were analyzed using real‐time PCR. Fusobacterium nucleatum density was significantly higher in nonresponders than in responders (3.2‐fold, p < 0.05) and controls (fivefold, p < 0.05). TNF‐α expression was elevated in both UC groups. These findings suggest F. nucleatum may contribute to anti‐TNF therapy resistance by modulating intestinal inflammation, highlighting its potential as a biomarker for treatment prediction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeFusobacterium nucleatumTumor Necrosis Factor-alphaHumansMaleFemaleAdultMiddle AgedReal-Time Polymerase Chain ReactionGastrointestinal Microbiome

Stichwörter der Autor:innen

Fusobacterium nucleatumTNF-αanti-TNF therapymicrobiota dysbiosisulcerative colitis

Substanzen

Tumor Necrosis Factor-alpha

Autor:innen und Institutionen

  • Department of Medical Biology, Ege University Faculty of Medicine, Izmir, Türkiye.
  • Department of Gastroenterology, Ege University Faculty of Medicine, Izmir, Türkiye.
  • Department of Pathology, Ege University Faculty of Medicine, Izmir, Türkiye.
  • Department of Microbiology, Ege University Faculty of Science, Izmir, Türkiye.

ORCID-Profile: Bilge Şenyüz, Nalan Gülşen Ünal, Başak Doğanavşargil Yakut, Ataç Uzel, Cumhur Gündüz, Sunde Yılmaz Süslüer

Zitieren

APA

Şenyüz, B., Ünal, N. G., Yakut, B. D., Uzel, A., Gündüz, C., & Süslüer, S. Y. (2025). Influence of Fusobacterium nucleatum on Tumor Necrosis Factor Alpha Therapy in Ulcerative Colitis. Mediators of Inflammation, 2025(1). https://doi.org/10.1155/mi/5035877

Vancouver

Şenyüz B, Ünal NG, Yakut BD, Uzel A, Gündüz C, Süslüer SY. Influence of Fusobacterium nucleatum on Tumor Necrosis Factor Alpha Therapy in Ulcerative Colitis. Mediators of Inflammation. 2025;2025(1). doi:10.1155/mi/5035877

BibTeX
@article{enyz2025,
  author = {Şenyüz, Bilge and Ünal, Nalan Gülşen and Yakut, Başak Doğanavşargil and Uzel, Ataç and Gündüz, Cumhur and Süslüer, Sunde Yılmaz},
  title = {Influence of Fusobacterium nucleatum on Tumor Necrosis Factor Alpha Therapy in Ulcerative Colitis},
  journal = {Mediators of Inflammation},
  year = {2025},
  volume = {2025},
  number = {1},
  doi = {10.1155/mi/5035877}
}
Kostenlos starten →